WO2006078766A3 - Methods and compositions for metastatic tumor screening - Google Patents

Methods and compositions for metastatic tumor screening Download PDF

Info

Publication number
WO2006078766A3
WO2006078766A3 PCT/US2006/001819 US2006001819W WO2006078766A3 WO 2006078766 A3 WO2006078766 A3 WO 2006078766A3 US 2006001819 W US2006001819 W US 2006001819W WO 2006078766 A3 WO2006078766 A3 WO 2006078766A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying
tumor
antigens
lymph nodes
Prior art date
Application number
PCT/US2006/001819
Other languages
French (fr)
Other versions
WO2006078766A2 (en
Inventor
Kevin Claffey
Original Assignee
Univ Connecticut
Kevin Claffey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut, Kevin Claffey filed Critical Univ Connecticut
Publication of WO2006078766A2 publication Critical patent/WO2006078766A2/en
Publication of WO2006078766A3 publication Critical patent/WO2006078766A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Abstract

Methods are described for identifying immunologically reactive lymph nodes in human patients, isolating or preparing variable region recombinant proteins, identifying antigens in tumor and tissue extracts, and identifying activated germinal centers in tumor-draining and pathologically reactive-lymph nodes. The antigens and proteins may be employed as diagnostics and therapeutics for cancers and other pathological conditions. Also described are methods for screening biological samples for early tumor metastases. Stromal cell derived receptor-1/Neuroplastin gp65/55 is described as a marker of invasive potential in human tumors.
PCT/US2006/001819 2005-01-19 2006-01-19 Methods and compositions for metastatic tumor screening WO2006078766A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64506005P 2005-01-19 2005-01-19
US60/645,060 2005-01-19

Publications (2)

Publication Number Publication Date
WO2006078766A2 WO2006078766A2 (en) 2006-07-27
WO2006078766A3 true WO2006078766A3 (en) 2007-08-02

Family

ID=36692841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001819 WO2006078766A2 (en) 2005-01-19 2006-01-19 Methods and compositions for metastatic tumor screening

Country Status (1)

Country Link
WO (1) WO2006078766A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168382A1 (en) * 2007-06-12 2010-07-01 Vladimir Berezin Neuroplastin derived peptides
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System Tumor specific antibodies and t-cell receptors and methods of identifying the same
EP3995178A1 (en) * 2020-11-09 2022-05-11 Université de Genève Method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2003030833A2 (en) * 2001-10-11 2003-04-17 Amgen Inc. Angiopoietin-2 specific binding agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2003030833A2 (en) * 2001-10-11 2003-04-17 Amgen Inc. Angiopoietin-2 specific binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUPSCH J.-M. ET AL.: "Isolation of Human Tumor-Specific Antibodies by Selection of an Antibody Phage Library on Melanoma Cells", CLINICAL CANCER RESEARCH, vol. 5, April 1999 (1999-04-01), pages 925 - 931, XP002993528 *

Also Published As

Publication number Publication date
WO2006078766A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
Shingaki et al. Evaluation of histopathologic parameters in predicting cervical lymph node metastasis of oral and oropharyngeal carcinomas
EP2258873A3 (en) Gene expression profiling in biopsied tumor tissues
WO2004072117A3 (en) Antibodies to c-met for the treatment of cancers
WO2000031303A3 (en) Methods for stool sample preparation
CA2425761A1 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
WO2004065547A3 (en) Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
WO2001055312A8 (en) Nucleic acids, proteins, and antibodies
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
TW200604208A (en) Antibodies to angiogenesis inhibiting domains of CD148
WO2007079293A3 (en) Cancer stem cells and uses thereof
WO1998010069A3 (en) E25a protein, methods for production and use thereof
WO2000053728A3 (en) Method for cultivating cancer cells from human tissue and device for preparing tissue samples
WO2006039405A3 (en) Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods and kits thereof
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2006044330A3 (en) Anticancer compounds and methods
WO2006078766A3 (en) Methods and compositions for metastatic tumor screening
ATE283483T1 (en) TUMOR-SPECIFIC P450 PROTEIN
Mehregan Aggressive basal cell epithelioma on sunlight-protected skin: report of eight cases, one with pulmonary and bone metastases
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
WO2004006860A3 (en) Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
CN101493464A (en) Molecular marker for breast carcinoma diagnosis
WO2003079884A3 (en) Methods for diagnosis and prognosis of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06733749

Country of ref document: EP

Kind code of ref document: A2